MDC Max Delbrück Center for Molecular Medicine in the Helmholtz Association

The MDC Max Delbrück Center for Molecular Medicine in the Helmholtz Association ranks among the top institutions in the world for basic biomedical research. MDC scientists use state-of-the-art methods of molecular biology and genetic engineering in order to understand the development of complex diseases at their origin, in the genes. On this basis, they seek to develop new methods to diagnose, treat and prevent diseases. Research activities at the MDC are divided into four main areas: cardiovascular and metabolic diseases, cancer, diseases of the nervous system and medical systems biology. MDC researchers collaborate closely with the Charité in the Experimental and Clinical Research Center and also with biotech companies located on Campus Berlin-Buch. The MDC currently employs approximately 1,700 staff members, including guest scientists, and has state-of-the-art technology platforms such as 7 Tesla ultra high field MRI, electron microscopy or bioinformatics.

Leibniz Research Institute for Molecular Pharmacology (FMP)
How do diseases develop? Which drugs can specifically target and intervene in the biochemistry of the body? Research activities at the Leibniz Research Institute for Molecular Pharmacology (FMP), Germany’s only non-university research institute for pharmacology, are concerned with these questions. Chemists, biologists, pharmacologists, physicists and physicians collaborate closely to lay the basis for the development of future drugs.
The FMP cooperates with other Berlin research institutions such as the Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin and is part of several research projects, such as the Neurocure cluster of excellence. The institute is also one of the initiators of the large-scale European project EU-OPENSCREEN, in which institutions from various European countries want to coordinate the search for new drugs, and part of the new European network “Instruct”, which seeks to link the highly sophisticated technologies in structural biology.
The institute has a staff of 300 employees and is a member of the Leibniz Association and the Forschungsverbund Berlin e.V. (Berlin Research Association).
News research
Max Delbrück Center to host Helmholtz Drug Discovery meeting
Top scientists and companies will meet in Berlin-Buch for the 2025 Helmholtz Drug Discovery Conference from April 28-30 to discuss RNA drugs, PROTACs, AI in drug discovery, and chemoproteomics and to ...
more ...Eckert & Ziegler Signs Contract Manufacturing Agreement for Yttrium-90-based PentixaTher with Pentixapharm
Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical compan...
more ...Talk im Cube: "International Cooperation and Funding programs in Life Sciences"
On May 15, we will feature four esteemed experts in the field who will share their insights and experiences on the importance of collaboration across borders and the role of funding in advancing life ...
more ...Events Campus
06.05.2025, 19:30
Heißer Sand und Eis am Stiel - Wie unser Gehirn Temperatur erkennt
Einen Gegenstand zu berühren und sofort zu erkennen, ob er warm oder kalt ist erscheint uns natürlich. Aber wie funktioniert das eigentlich? Wo und wie verarbeitet das Gehirn die Temperaturinformation...
more ...07.05.2025, 16:00
Labor trifft Lehrer: "Retinale Bildgebung: Das Auge als Fenster zum Gehirn"
mit Dr. Frederike Oertel
more ...15.05.2025, 17:00
Talk im Cube: "International Cooperation and Funding programs in Life Sciences"
This event will feature four esteemed experts in the field who will share their insights and experiences on the importance of collaboration across borders and the role of funding in advancing life sc...
more ...